These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15373035)

  • 1. [Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():14-6. PubMed ID: 15373035
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interview with Professor Jürgen Rockstroh, director of the Bonn University Clinic. Atazanavir in general practice].
    Rockstroh J
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-9. PubMed ID: 15373037
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term tolerance. Favorable lipid profile--favorable effect on development of lipodystrophy?].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():17. PubMed ID: 15373036
    [No Abstract]   [Full Text] [Related]  

  • 6. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMS-232632, a new protease inhibitor, is taken once daily.
    Gaylord G
    Posit Living; 2000 Jul; 9(6):22. PubMed ID: 12492017
    [No Abstract]   [Full Text] [Related]  

  • 8. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065
    [No Abstract]   [Full Text] [Related]  

  • 9. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

  • 10. [Progress toward a once daily regimen. (HA)ART--the art of antiretroviral therapy].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():78-9. PubMed ID: 11373790
    [No Abstract]   [Full Text] [Related]  

  • 11. [Efficacy of atazanavir in simplification regimens].
    Zamora L; Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():14-21. PubMed ID: 20116612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for "once daily" administration].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():14-5. PubMed ID: 15011577
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-HIV agents. Kaletra + atazanavir.
    TreatmentUpdate; 2005; 17(5):5. PubMed ID: 17219657
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
    Huff B
    GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
    [No Abstract]   [Full Text] [Related]  

  • 17. Boosted Reyataz: 48-week results.
    Huff B
    GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
    [No Abstract]   [Full Text] [Related]  

  • 18. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract]   [Full Text] [Related]  

  • 19. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Highly effective and tolerable protease inhibitor. New trump card against HIV].
    MMW Fortschr Med; 2003 Jan; 145(1-2):55. PubMed ID: 12638446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.